VRC304 - A Phase I Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine (VRC-AVIDNA036-00-VP) Encoding for the Influenza Virus H5 Hemagglutinin Protein in Healthy Adults
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://immport.org/shared/study/SDY167
下载链接
链接失效反馈官方服务：
资源简介：
VRC304 - A Phase I, double-blind, placebo-controlled, randomized, dose escalation study to evaluate safety, tolerability, and immunogenicity of a recombinant DNA vaccine against the influenza virus hemagglutinin H5.
创建时间：
2025-10-30
